Category: News

Post

Nabriva Therapeutics to Present at the BofA Securities 2020 Virtual Health Care Conference

DUBLIN, Ireland, May 11, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the BofA Securities 2020 Virtual Health...

Post

Nabriva Therapeutics to Report First Quarter 2020 Financial Results on May 11, 2020

DUBLIN, Ireland, May 08, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will report its first quarter financial results after the close of the U.S. financial markets on Monday, May 11, 2020. Nabriva’s...

Post

SCYNEXIS Announces Six Abstracts Published by 30th ECCMID Highlighting the Potential Clinical Utility of Ibrexafungerp

SCYNEXIS Announces Six Abstracts Published by 30th ECCMID Highlighting the Potential Clinical Utility of Ibrexafungerp Oral ibrexafungerp continues to show potential to address a broad range of indications ranging from vaginal yeast infections to life-threatening refractory invasive fungal infections Findings indicate oral ibrexafungerp could potentially decrease length of hospital...

Post

XENLETA® (Lefamulin) Treatment Results in a Rapid Time-to-Clinical Response in Hospitalized Patients with Community-Acquired Bacterial Pneumonia (CABP)

Results support Xenleta as an empiric, short-course monotherapy replacement for respiratory fluoroquinolones for treatment of CABP DUBLIN, Ireland, May 05, 2020 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that Open Forum Infectious Diseases, an official...

Post

Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational Progress

Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results for the Fourth Period and Eleven Months Ended December 31, 2019, and Operational Progress Oxford, UK, and Cambridge, MA, US, April 30, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today reports its financial results for the fourth period* and eleven months ended...

Post

Amplyx Pharmaceuticals to Participate in Antifungal Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector

SAN DIEGO – April 29, 2020 – Amplyx Pharmaceuticals, a clinical stage biotech company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, today announced that Ciara Kennedy, Ph.D., President and Chief Executive Officer, will participate in a panel discussing fungal pathogens and the emerging antifungal therapeutic landscape at the...

Post

SCYNEXIS to Participate in Antifungals Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector

SCYNEXIS to Participate in Antifungals Panel at Maxim Group’s Infectious Disease Virtual Conference: The Renaissance of the Anti-infective Sector JERSEY CITY, N.J., April 28, 2020 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that...

Post

SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)

SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection) Ibrexafungerp achieved highly statistically significant superiority over placebo for the primary and key secondary study endpoints Ibrexafungerp was generally safe and well-tolerated Positive results...